Bank of America
ALXN

Bank of America’s Alexion Pharmaceuticals ALXN Stock Holding History

Bank of America’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,429,070
Closed -$263M – 8681
2021
Q2 		$263M Buy
1,429,070
+486,240
+52% +$83.5M 0.03% 523
2021
Q1 		$144M Sell
942,830
-866,928
-48% -$134M 0.02% 720
2020
Q4 		$283M Sell
1,809,758
-175,612
-9% -$22.6M 0.04% 419
2020
Q3 		$227M Buy
1,985,370
+52,925
+3% +$5.71M 0.03% 455
2020
Q2 		$217M Buy
1,932,445
+133,997
+7% +$14.2M 0.03% 441
2020
Q1 		$161M Buy
1,798,448
+91,056
+5% +$8.94M 0.03% 479
2019
Q4 		$185M Sell
1,707,392
-315,781
-16% -$33.8M 0.03% 523
2019
Q3 		$198M Sell
2,023,173
-55,412
-3% -$6.25M 0.03% 486
2019
Q2 		$272M Buy
2,078,585
+4,926
+0.2% +$635K 0.04% 395
2019
Q1 		$280M Buy
2,073,659
+259,165
+14% +$32.2M 0.04% 372
2018
Q4 		$177M Sell
1,814,494
-423,532
-19% -$50.1M 0.03% 475
2018
Q3 		$311M Buy
2,238,026
+277,444
+14% +$34.8M 0.05% 355
2018
Q2 		$243M Sell
1,960,582
-261,517
-12% -$30.6M 0.04% 400
2018
Q1 		$248M Buy
2,222,099
+597,384
+37% +$71.4M 0.04% 399
2017
Q4 		$194M Sell
1,624,715
-506,370
-24% -$61.7M 0.03% 454
2017
Q3 		$299M Buy
2,131,085
+389,910
+22% +$53M 0.05% 361
2017
Q2 		$212M Buy
1,741,175
+100,866
+6% +$11.7M 0.04% 408
2017
Q1 		$199M Sell
1,640,309
-80,484
-5% -$10.4M 0.04% 408
2016
Q4 		$211M Sell
1,720,793
-134,987
-7% -$16.5M 0.05% 400
2016
Q3 		$227M Sell
1,855,780
-189,384
-9% -$24.4M 0.05% 357
2016
Q2 		$239M Sell
2,045,164
-511,254
-20% -$72.5M 0.06% 334
2016
Q1 		$356M Sell
2,556,418
-103,071
-4% -$15.1M 0.09% 240
2015
Q4 		$507M Buy
2,659,489
+342,899
+15% +$59.9M 0.12% 193
2015
Q3 		$362M Buy
2,316,590
+1,217,011
+111% +$222M 0.09% 229
2015
Q2 		$199M Buy
1,099,579
+100,790
+10% +$17.4M 0.06% 322
2015
Q1 		$173M Sell
998,789
-30,951
-3% -$5.6M 0.06% 344
2014
Q4 		$191M Sell
1,029,740
-66,950
-6% -$12.4M 0.07% 329
2014
Q3 		$182M Sell
1,096,690
-8,465
-0.8% -$1.39M 0.06% 353
2014
Q2 		$173M Sell
1,105,155
-77,874
-7% -$12.3M 0.06% 368
2014
Q1 		$180M Buy
1,183,029
+38,397
+3% +$6.11M 0.07% 306
2013
Q4 		$152M Sell
1,144,632
-83,847
-7% -$10.1M 0.05% 353
2013
Q3 		$143M Buy
1,228,479
+26,690
+2% +$2.93M 0.06% 341
2013
Q2 		$111M Buy
+1,201,789
New +$116M 0.05% 388

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Bank of America's ALXN Position: Q3 2021 in Review

Bank of America sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 1,429,070 shares — an estimated $263M sold.

Bank of America first reported a position in ALXN in Q2 2013 and held it in 33 quarters. The position peaked at $507M in Q4 2015. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Bank of America reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Bank of America sold 1,429,070 Alexion Pharmaceuticals shares in Q3 2021, an estimated $263M.
  • Bank of America first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 33 quarters.
  • Bank of America's Alexion Pharmaceuticals position peaked at $507M in Q4 2015.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Bank of America's 13F filing for Q3 2021, filed 15 Nov 2021.